Results 1 to 10 of about 256,231 (309)

Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review [PDF]

Cancer Treatment Reviews, 2007
Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with ...
Britta Stordal, Nick Pavlakis, Ross Davey   +2 more
exaly   +2 more sources

A cyclin D1–CDK4/6–E2F dependency represents an acquired vulnerability in cisplatin-resistant bladder cancer [PDF]

Biology Direct
Background Cisplatin resistance remains a major obstacle in the treatment of bladder cancer (BC). This study aimed to define molecular drivers of cisplatin resistance and to assess potential therapeutic targets that may help restore treatment ...
Tsung-Han Hsieh, Han-Pin Kuo, Chun-Hsu Pan, Yu-Chen Lin, Bo-Jyun Lin, Mei-Chuan Chen, Chun-Han Chen   +6 more
doaj   +2 more sources

Metabolomics unveils the mechanism of Bufei Huayu decoction in combination with cisplatin against non-small cell lung cancer (NSCLC)

Heliyon, 2023
Introduction: Bufei Huayu Decoction (BFHY) is a clinical prescription with reported efficacy in enhancing the therapeutic outcomes of chemotherapeutic agents for non-small cell lung cancer (NSCLC).
Yuan Feng, Ying Jiang, Ying Zhou, Zhan-hua Li, Qi-qian Yang, Jin-feng Mo, Yu-yan Wen, Li-ping Shen   +7 more
doaj   +1 more source

Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. [PDF]

PLoS ONE, 2014
Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) reduces survival. In this study we hypothesized that methylation of key genes mediates cisplatin resistance.
Chi T Viet, Dongmin Dang, Stacy Achdjian, Yi Ye, Samuel G Katz, Brian L Schmidt   +5 more
doaj   +1 more source

Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity

Scientific Reports, 2021
Cisplatin, one of the most active anticancer agents, is widely used in standard chemotherapy for various cancers. Cisplatin is more poorly tolerated than other chemotherapeutic drugs, and the main dose-limiting toxicity of cisplatin is its nephrotoxicity,
Masashi Arita, Satoshi Watanabe, Nobumasa Aoki, Shoji Kuwahara, Ryo Suzuki, Sawako Goto, Yuko Abe, Miho Takahashi, Miyuki Sato, Satoshi Hokari, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Masachika Hayashi, Yasuyoshi Ohshima, Hideyuki Kabasawa, Michihiro Hosojima, Toshiyuki Koya, Akihiko Saito, Toshiaki Kikuchi   +21 more
doaj   +1 more source

Protective Effect of Moderate-Intensity Continuous Training and High-Intensity Interval Training on Serum Levels of Oxidative Stress Parameters in Rats Treated with Cisplatin [PDF]

Journal of Mazandaran University of Medical Sciences, 2023
Background and purpose: Considering the antioxidant properties of physical activity, the aim of the present study was to investigate the effect of moderate-intensity continuous training (MICT) and high-intensity intermittent training (HIIT) on oxidative ...
Mohammad Parastesh, Yusef Abbasi, Mohammad Reza Bayatiani, Zahra Nadi   +3 more
doaj   +2 more sources

Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness

Thoracic Cancer, 2020
Background Lung cancer is the leading cause of cancer death and is commonly treated by cisplatin. Although cisplatin treatment may initially be successful, its effectiveness usually reduces significantly in disease‐recurrent patients.
Maoyuan Zhao, Ting Wang, Zhouguang Hui
doaj   +1 more source

Investigation of Astaxanthin Effect on Cisplatin Ototoxicity in Rats by Using Otoacoustic Emission, Total Antioxidant Capacity, and Histopathological Methods

Ear, Nose & Throat Journal, 2021
Background: Cisplatin-induced ototoxicity is related to oxidative stress. Astaxanthin is one of the most powerful antioxidants in nature. Aims/objectives: To investigate the protective effect of astaxanthin on cisplatin-induced ototoxicity. Materials and
M. Emrah Kınal MD, Arzu Tatlıpınar MD, Selami Uzun MD, Serhan Keskin MD, Emrah Tekdemir MD, Dilek Özbeyli PhD, Dilek Akakın MD   +6 more
doaj   +1 more source

Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer

Journal of Immunology Research, 2022
Objective. Evidence demonstrates that the immune microenvironment is extensively associated with chemotherapy response of ovarian cancer (OV). Herein, this study is aimed at establishing a cisplatin response prediction model for OV on the basis of immune
Ying Guo, Na Yang, Gang Li, Xiurong Yin, Lixia Dong   +4 more
doaj   +1 more source

A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer

BMC Cancer, 2022
Background Concurrent chemoradiotherapy (CCRT) has become the cornerstone of treatment for patients with locally advanced non-small cell lung cancer (LA-NSCLC). The aim of this study was to compare the efficacies and toxicities of different CCRT regimens
Qiangqiang Zheng, Shihui Min, Yunfeng Zhou   +2 more
doaj   +1 more source